Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD) announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:30 a.m. ET in New York, NY.

A live and archived webcast will be available in the Events & Presentations section of Boundless Bio's Investors website.

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference.

The fireside chat session is scheduled for Wednesday, December 3, in New York, NY, at 9:30 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR). These compounds are being evaluated in combination in patients with oncogene amplified cancers in the Company’s phase 1/2 POTENTIATE clinical trial. Boundless Bio is conducting IND-enabling studies of another ecDTx, BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Investor Contacts:
James Lee, Boundless Bio, Inc.
jlee@boundlessbio.com

Renee Leck, THRUST Strategic Communications
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST Strategic Communications
carly@thrustsc.com

FAQ

When will Boundless Bio (BOLD) present at the Piper Sandler 37th Annual Healthcare Conference?

The fireside chat is scheduled for Wednesday, December 3, 2025 at 9:30 a.m. ET in New York.

Who from Boundless Bio will speak at the Piper Sandler conference for BOLD?

Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will participate in the fireside chat.

How can investors watch the Boundless Bio (BOLD) Piper Sandler fireside chat?

A live and archived webcast will be accessible under Events & Presentations in the Investors section of Boundless Bio's website.

What topics will Boundless Bio (BOLD) likely cover at the December 3, 2025 fireside chat?

The company is a clinical-stage oncology firm focused on ecDNA biology and oncogene amplified cancers, which are expected topics during the presentation.

Where and when is the Piper Sandler 37th Annual Healthcare Conference taking place for BOLD's presentation?

The session takes place in New York, NY on December 3, 2025 at 9:30 a.m. ET.